Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alemtuzumab - Bayer/Sanofi/University of Cambridge

Drug Profile

Alemtuzumab - Bayer/Sanofi/University of Cambridge

Alternative Names: Anti-CD52 monoclonal antibody; Campath; Campath-1H; LDP-03; Lemtrada; MabCampath; MabKampat; Remniq

Latest Information Update: 10 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Cambridge
  • Developer Bayer HealthCare Pharmaceuticals Inc.; Dana-Farber Cancer Institute; German CLL Study Group; Ohio State University Comprehensive Cancer Center; Sanofi; Sanofi Oncology; University of Cologne
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD52 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Multiple sclerosis
  • Phase II T-cell prolymphocytic leukaemia
  • Phase I Lymphoma
  • No development reported Diffuse large B cell lymphoma; Graft-versus-host disease; Sezary syndrome; T-cell lymphoma
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 31 Oct 2019 Pharmacovigilance Risk Assessment Committee recommendes to restrict the use of alemtuzumab in adults with multiple sclerosis
  • 12 Jun 2019 Genzyme and Brigham and Women's Hospital plan a phase I/II trial to observe effect of alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple sclerosis in USA in July 2019 (NCT03983252)
  • 28 May 2019 Genzyme completes a phase LemCourse IIIb trial in Multiple sclerosis in Germany (IV) (EudraCT2016-000464-42)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top